Would you get a one-time genetic modification such that you'd never have to take a GLP-1 drug for weight loss ever again?

University of Osaka researchers used genome editing to program mouse liver cells to produce exenatide, a weight-loss drug.

Weight-loss drugs have surged in popularity, promising rapid results with regular injections. Now, researchers from Japan ...

A large-scale clinical trial found that intravenous infusion of exenatide, a glucagon-like peptide-1 (GLP-1) analog medication, during heart surgeries involving bypass did not significantly reduce ...

Adults with type 1 diabetes on multiple daily injection therapy saw no benefit in glycemic measures when adding on preprandial injections of short-acting exenatide, according to findings from a ...

Weekly injections of the GLP-1 receptor agonist exenatide (Byetta, Bydureon) did not slow Parkinson's disease progression or improve symptoms, the phase III Exenatide-PD3 trial showed.

Researchers create a one-time genome editing introducing a GLP-1 receptor agonist, resulting in long-term appetite ...

FRIDAY, Feb. 7, 2025 (HealthDay News) -- The glucagon-like peptide-1 receptor agonist exenatide does not yield improvement in measures of Parkinson disease severity, according to a study published ...

A study in the United Kingdom involved 194 people with Parkinson’s disease who were randomly assigned to inject themselves once a week with exenatide, marketed as Byetta, or with a placebo ...

Treatment with once-weekly exenatide was not associated with improvements in patients with Parkinson disease, according to findings from a study published in The Lancet.

New data suggest Vivani’s miniature exenatide implant, NPM-115, works as well as Novo Nordisk’s Wegovy and Ozempic for weight loss in mice.